u/yara_mensah

Is that the same assay, or did the lab change platforms?

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

The press release said that; the publication says something more hedged. Worth reading both.

the appetite effect makes eating enough protein a logistics problem

nobody legitimate needs the payment in the next ten minutes

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

If the report gives a mass spectrum as well as UV purity, say so. Identity and relative quantity are separate claims and the log tracks both.

Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.

Push back: strength dropping in a deficit is not the same as lean mass loss. Related, not identical.

Is there any independent purity data on this compound that you have seen?

Inter-lab variance on this assay runs roughly a point either way, driven mostly by gradient and integration. Two results inside that band agree; they do not disagree quietly.

Sent to the right address on the wrong chain years ago. Nothing to be done. That is the lesson I paid for.

Same. A press release is a claim about a result; the publication is the result.

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

What did the confidence interval look like?

a mean is not a promise

Have you taken this to whoever ordered it?

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

Hydration status and fasting state affect the lean mass estimate. Standardising both is the difference between a comparison and a coin toss.

date of analysis matters as much as the number

Correction: that marker is reported in different units by different labs, which explains the tenfold difference you are seeing.

Disagreeing with this bit: that change is confounded by the weight loss itself and cannot be attributed.

What was the comparator?

How many weeks between the two measurements?

Do you have the publication or the press release?

amylin analogue, different receptor family, different story

Do you have the publication or the press release?

What did the confidence interval look like?

nothing on this board interprets your results for you

Retitled: the original quoted a diabetes endpoint as an obesity result.

hazard_ratio_hal is right about the programme names. They are different populations with different endpoints.

Right, and confirmations are the status.

This is the check that prevents the only genuinely unrecoverable mistake in this thread.

Rate quotes expire because the underlying rate moves.

Disagreeing here: that is a network fee at a busy hour and it is not the supplier’s doing.

Which trial, and which arm?

Is that intention-to-treat or completers?

The registered protocol is public.

Adding the check nobody runs — the registered protocol is public and takes two minutes to compare.

Agreed. The trend is the signal. A single value is a snapshot of one morning.

My ferritin moved and I spent a fortnight convinced I knew why. The repeat six weeks later was back in range and I had changed nothing.

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable